Isotope-labeled amino acids are highly valuable and versatile tools to accelerate fundamental and translational research and tackle complex biological questions. Current production processes are, however, low-yielding, expensive and time-intensive, and cannot be applied to all amino acids, leading to missed opportunities and inefficient use of resources. In this ERC PoC project, we have addressed these limitations and developed an innovative and more efficient method to produce such isotope-labeled amino acids. We expanded and optimized the production protocols and provided important proof-of-concept data underpinning the commercial feasibility of this technology. With these data and the underlying intellectual property, we were able to raise further funding to help establish a spin-off company. Anticipated outcomes of successful commercialization of our technology include economic benefits for the EU, strengthening EU’s leadership in biotech and innovation, and technological advancements that will create new research avenues, improve research translation and disease management, and lead to an overall improvement of health and well-being.